Irradiation of muscle precursor cells impairs the proliferative and angiogenic functions of their extracellular vesicles
Sharma U., Pacelli S., Meledeo MA., Bynum JA., Rathbone CR.
Animal Study, published in Sci Rep (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Sci Rep (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40835994
- PMCID
- PMC12368205
- DOI
- 10.1038/s41598-025-15699-x
- Citations
- 1
Abstract (original English)
Ionizing radiation exposure, whether from accidental incidents, radiation therapy, or radiological weapons, poses a significant risk to public health and military personnel. Survivors experience both acute and chronic physiological effects, including tissue dysfunction, fibrosis, and impaired organ function. Among affected tissues, skeletal muscle is particularly vulnerable, as radiation damages muscle precursor cells (MPCs), impairing their ability to regenerate and maintain muscle homeostasis. Extracellular vesicles (EVs), nano-sized lipid-bound vesicles released by cells, mediate intercellular communication by transferring bioactive molecules such as proteins, lipids, and microRNAs. EVs derived from MPCs have shown promise in promoting muscle regeneration, yet their role in radiation injury remains unclear. This study investigated whether EVs from healthy MPCs (NoRad-EVs) could improve cell function in irradiated cells compared to EVs from irradiated MPCs (Rad-EVs). Our findings demonstrated that viability and proliferation are improved in irradiated MPCs receiving NoRad-EVs whereas Rad-EVs fail to mitigate radiation-induced damage. Specifically, NoRad-EVs increased MPC viability from 52 ± 5.7% to 71 ± 4.9% and improved BrdU-measured proliferation by ~ 16% compared to untreated irradiated controls. NoRad-EVs also enhanced angiogenesis in human umbilical vein endothelial cell
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.